Macquarie $210.50, Xero $155 and Wisetech $95 Close Higher as Nasdaq +1.4% - 24 Oct 2026

Macquarie $210.50, Xero $155 and Wisetech $95 Close Higher as Nasdaq +1.4% - 24 Oct 2026

MQG $210.50 +1.5%, XRO $155 +2.2%, WTC $95 +1.9% as Nasdaq +1.4% on Apple $89.5B revenue.

Macquarie $210.50, Xero $155 and Wisetech $95 Close Higher as Nasdaq +1.4% - 24 Oct 2026

Published: 24 Oct 2026 | Banking & Tech • ASX

Macquarie Group closed at $210.50 (+1.5%), Xero at $155 (+2.2%), Wisetech at $95 (+1.9%) after Nasdaq closed +1.4% overnight. Apple reported $89.5B revenue vs $87.5B expected. MQG has reported US exposure ~35% of profit per company annual report. Xero reported subscriber growth 12% YoY.

Publicly Reported Metrics - Educational

CompanyLast PriceReported PEReported Metric
MQG$210.50~16x (reported)AUM $900B reported, ROE 15%
XRO$155~85xSubscribers 1M+ reported, ARPU $38
WTC$95~60xRevenue growth 28% reported

Why Tech Higher - Factual Reports

  • Apple revenue $89.5B vs $87.5B expected, iPhone $43B vs $41B, Services $25B +12% YoY
  • Fed dovish minutes: 70% chance of Dec cut per CME FedWatch
  • US 10Y yield down to 4.08% from 4.25% - helps long-duration tech valuations
  • ASX tech correlation with Nasdaq historically ~0.65 (CommSec research)

Educational Context: High PE ratios for XRO/WTC reflect market expectations of growth, but high PE also implies higher risk if growth slows. MQG is diversified across asset management, banking, and commodities. Past performance of these companies does not indicate future performance. This is factual data from public reports for learning purposes, not a recommendation to buy, sell or hold.

Disclaimer

General Information & Educational Purposes Only: This article is general information and for educational purposes only. It does not take into account your personal objectives, financial situation or needs, and does not constitute financial product advice. It is not personal financial advice and should not be relied upon as such. Past performance, examples, historical data, or projections are not indicative of future results. You should consider whether it is appropriate for you, read the relevant Product Disclosure Statement (PDS), and seek independent professional advice from a licensed adviser before making any investment decision. While we endeavour to ensure accuracy, we make no representations or warranties regarding completeness or reliability. Data may include third-party sources including company announcements and regulatory filings which we do not independently verify. To the maximum extent permitted by law, Falkon Analytics excludes all liability for reliance on this information.